| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| GTO ID | GTC1162 |
| Trial ID | NCT00004070 |
| Disease | Head and Neck Cancer |
| Altered gene | IL-12A|IL-12B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | pIL-12 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Year | 1999 |
| Country | United States |
| Company sponsor | Dana-Farber Cancer Institute |
| Other ID(s) | 99-081|P30CA006516|VALENTIS-DFCI-99081|NCI-G99-1578|CDR0000067274 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||